This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content

(Circulation. 2003;108:2723.)
© 2003 American Heart Association, Inc.

Late-Breaking Clinical Trial Abstracts

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Heart Disease on the Mend: A Multifactor Risk Reduction Program in the Medically Underserved
William Haskell, Kathy Berra, Annette Clark, Dianne Christopherson, Shauna Duff, Jan George, Linda Klieman, Jeff Myll, Stanford University School of Medicine

Background: Risk factors contributing to increased risk for cardiovascular disease (CVD) are well defined. Clinical trials have shown that multifactor risk reduction (MRR) reduces CVD morbidity and mortality. The challenge is to implement cost-effective MRR programs, especially for ethnic minority and low-income populations. Purpose: To test the effectiveness of an MRR program in the medically underserved. Methods: Persons at high risk for CVD were identified in settings where low-income patients obtain medical care in Santa Clara County, Calif. Medical history and clinical screening confirmed eligibility. Eligible participants were randomized (2:1—treatment [T] versus usual care [UC]) into the Heart Disease on the Mend (HDOM) yearlong MRR program. The MRR program used a physician-directed, nurse and dietitian case management approach that included lifestyle change and medical management. Results: Of the 149 persons randomized, 56% were female, with mean age of 57 years (s.d.=20.4). Ethnicity included 57% Hispanic, 10% Asian, 7% African American, 16% Caucasian, and 10% other. Patient fluency in English: none=45%, moderate=22%, and fluent=33%. Presence of type II diabetes (54%), dyslipidemia (67%), hypertension (70%), and obesity (38%) were the most common CVD risk factors at baseline. Data at 12 months were collected on 91% of patients. The MRR program produced significant reductions in major CVD risk factors during follow-up for T vs UC. Risk status was lower at follow-up (6-month plus 12-month values) for T vs UC (ANCOVA) for the . . . [Full Text of this Article]

This article has been cited by other articles:

				R. Corti, V. Fuster, Z. A. Fayad, S. G. Worthley, G. Helft, W. F. Chaplin, J. Muntwyler, J. F. Viles-Gonzalez, J. Weinberger, D. A. Smith, et al. Effects of Aggressive Versus Conventional Lipid-Lowering Therapy by Simvastatin on Human Atherosclerotic Lesions: A Prospective, Randomized, Double-Blind Trial With High-Resolution Magnetic Resonance Imaging J. Am. Coll. Cardiol., July 5, 2005; 46(1): 106 - 112. [Abstract] [Full Text] [PDF]

				M. O'Donnell, G. Agnelli, and J. I. Weitz Emerging therapies for stroke prevention in atrial fibrillation Eur. Heart J. Suppl., May 1, 2005; 7(suppl_C): C19 - C27. [Abstract] [Full Text] [PDF]

				P. Madeddu Therapeutic angiogenesis and vasculogenesis for tissue regeneration Exp Physiol, May 1, 2005; 90(3): 315 - 326. [Abstract] [Full Text] [PDF]

				J. L. Halperin Ximelagatran: Oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation J. Am. Coll. Cardiol., January 4, 2005; 45(1): 1 - 9. [Abstract] [Full Text] [PDF]

				W. E Dager, T. G Vondracek, B. A McIntosh, and E. A Nutescu Ximelagatran: An Oral Direct Thrombin Inhibitor Ann. Pharmacother., November 1, 2004; 38(11): 1881 - 1897. [Abstract] [Full Text] [PDF]

				P. P. Dobesh, K. Kim, and Z. Stacy The Future of Anticoagulation Journal of Pharmacy Practice, October 1, 2004; 17(5): 370 - 384. [Abstract] [PDF]

				D. E. Singer, G. W. Albers, J. E. Dalen, A. S. Go, J. L. Halperin, and W. J. Manning Antithrombotic Therapy in Atrial Fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 429S - 456S. [Abstract] [Full Text] [PDF]

				J. Honold, B. Assmus, R. Lehman, A. M. Zeiher, and S. Dimmeler Stem cell therapy of cardiac disease: an update Nephrol. Dial. Transplant., July 1, 2004; 19(7): 1673 - 1677. [Full Text] [PDF]

				D. W. Losordo and S. Dimmeler Therapeutic Angiogenesis and Vasculogenesis for Ischemic Disease: Part II: Cell-Based Therapies Circulation, June 8, 2004; 109(22): 2692 - 2697. [Full Text] [PDF]

				M. S. Lee and R. R. Makkar Stem-Cell Transplantation in Myocardial Infarction: A Status Report Ann Intern Med, May 4, 2004; 140(9): 729 - 737. [Abstract] [Full Text] [PDF]

				J. T. Beranek, C. B. Granger, K. W. Mahaffey, W. D. Weaver, P. Theroux, J. S. Hochman, T. G. Filloon, T. G. Todaro, S. Rollins, C. F. Mojcik, et al. Why Did the Anti-C5 Complement Antibody Pexelizumab Not Reduce Infarct Size but Influence Clinical Outcomes Positively When Applied as Adjunctive Therapy to Primary Percutaneous Coronary Intervention? * Response Circulation, April 27, 2004; 109(16): e195 - e196. [Full Text] [PDF]

				R. T. Gansevoort, P. E. de Jong, and M. J. Postma Cost-effectiveness of Screening for Proteinuria JAMA, March 24, 2004; 291(12): 1442 - 1443. [Full Text] [PDF]